Browsing by Author Bafaloukos, D.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jump to: Α Β Γ Δ Ε Ζ Η Θ Ι Κ Λ Μ Ν Ξ Ο Π Ρ Σ Τ Υ Φ Χ Ψ Ω
or enter first few letters:  
View Option
Showing results 29 to 48 of 60 < previous   next >
TitleAuthor(s)Issue date???itemlist.???
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluationFountzilas, G.; Kourea, H. P.; Bobos, M.; Televantou, D.; Kotoula, V.; Papadimitriou, C.; Papazisis, K. T.; Timotheadou, E.; Efstratiou, I.; Koutras, A.; Pentheroudakis, G.; Christodoulou, C.; Aravantinos, G.; Miliaras, D.; Petraki, K.; Papandreou, C. N.; Papakostas, P.; Bafaloukos, D.; Repana, D.; Razis, E.; Pectasides, D.; Dimopoulos, A. M.24-Nov-2015-
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology GroupFountzilas, G.; Pectasides, D.; Kalogera-Fountzila, A.; Skarlos, D.; Kalofonos, H. P.; Papadimitriou, C.; Bafaloukos, D.; Lambropoulos, S.; Papadopoulos, S.; Kourea, H.; Markopoulos, C.; Linardou, H.; Mavroudis, D.; Briasoulis, E.; Pavlidis, N.; Razis, E.; Kosmidis, P.; Gogas, H.24-Nov-2015-
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology GroupFountzilas, G.; Kalofonos, H. P.; Dafni, U.; Papadimitriou, C.; Bafaloukos, D.; Papakostas, P.; Kalogera-Fountzila, A.; Gogas, H.; Aravantinos, G.; Moulopoulos, L. A.; Economopoulos, T.; Pectasides, D.; Maniadakis, N.; Siafaka, V.; Briasoulis, E.; Christodoulou, C.; Tsavdaridis, D.; Makrantonakis, P.; Razis, E.; Kosmidis, P.; Skarlos, D.; Dimopoulos, M. A.24-Nov-2015-
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG)Kosmidis, P. A.; Fountzilas, G.; Eleftheraki, A. G.; Kalofonos, H. P.; Pentheroudakis, G.; Skarlos, D.; Dimopoulos, M. A.; Bafaloukos, D.; Pectasides, D.; Samantas, E.; Boukovinas, J.; Lambaki, S.; Katirtzoglou, N.; Bakogiannis, C.; Syrigos, K. N.24-Nov-2015-
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology GroupFountzilas, G.; Papakostas, P.; Dafni, U.; Makatsoris, T.; Karina, M.; Kalogera-Fountzila, A.; Maniadakis, N.; Aravantinos, G.; Syrigos, K.; Bamias, A.; Christodoulou, C.; Economopoulos, T.; Kalofonos, H.; Nikolaou, A.; Angouridakis, N.; Stathopoulos, G.; Bafaloukos, D.; Pavlidis, N.; Daniilidis, J.24-Nov-2015-
Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology GroupFountzilas, G.; Athanassiadis, A.; Kalogera-Fountzila, A.; Aravantinos, G.; Bafaloukos, D.; Briasoulis, E.; Dombros, N.; Ioannidis, I.; Pavlidis, N.; Kosmidis, P.; Skarlos, D.24-Nov-2015-
Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) studyAravantinos, G.; Fountzilas, G.; Kosmidis, P.; Dimopoulos, M. A.; Stathopoulos, G. P.; Pavlidis, N.; Bafaloukos, D.; Papadimitriou, C.; Karpathios, S.; Georgoulias, V.; Papakostas, P.; Kalofonos, H. P.; Grimani, E.; Skarlos, D. V.24-Nov-2015-
Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group studySkarlos, D. V.; Aravantinos, G.; Kosmidis, P.; Athanassiadis, A.; Stathopoulos, G. P.; Pavlidis, N.; Bafaloukos, D.; Karphathios, S.; Papakostas, P.; Bamia, C.; Fountzilas, G.24-Nov-2015-
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictorsPentheroudakis, G.; Fountzilas, G.; Kalofonos, H. P.; Golfinopoulos, V.; Aravantinos, G.; Bafaloukos, D.; Papakostas, P.; Pectasides, D.; Christodoulou, C.; Syrigos, K.; Economopoulos, T.; Pavlidis, N.24-Nov-2015-
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancerAravantinos, G.; Bafaloukos, D.; Fountzilas, G.; Christodoulou, C.; Papadimitriou, C.; Pavlidis, N.; Kalofonos, H. P.; Gogas, H.; Kosmidis, P.; Dimopoulos, M. A.24-Nov-2015-
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupFountzilas, G.; Skarlos, D.; Dafni, U.; Gogas, H.; Briasoulis, E.; Pectasides, D.; Papadimitriou, C.; Markopoulos, C.; Polychronis, A.; Kalofonos, H. P.; Siafaka, V.; Kosmidis, P.; Timotheadou, E.; Tsavdaridis, D.; Bafaloukos, D.; Papakostas, P.; Razis, E.; Makrantonakis, P.; Aravantinos, G.; Christodoulou, C.; Dimopoulos, A. M.24-Nov-2015-
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00Fountzilas, G.; Dafni, U.; Gogas, H.; Linardou, H.; Kalofonos, H. P.; Briasoulis, E.; Pectasides, D.; Samantas, E.; Bafaloukos, D.; Stathopoulos, G. P.; Karina, M.; Papadimitriou, C.; Skarlos, D.; Pisanidis, N.; Papakostas, P.; Markopoulos, C.; Tzorakoeleftherakis, E.; Dimitrakakis, K.; Makrantonakis, P.; Xiros, N.; Polichronis, A.; Varthalitis, I.; Karanikiotis, C.; Dimopoulos, A. M.24-Nov-2015-
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III TrialGogas, H.; Dafni, U.; Karina, M.; Papadimitriou, C.; Batistatou, A.; Bobos, M.; Kalofonos, H. P.; Eleftheraki, A. G.; Timotheadou, E.; Bafaloukos, D.; Christodoulou, C.; Markopoulos, C.; Briasoulis, E.; Papakostas, P.; Samantas, E.; Kosmidis, P.; Stathopoulos, G. P.; Karanikiotis, C.; Pectasides, D.; Dimopoulos, M. A.; Fountzilas, G.24-Nov-2015-
Predictive and Prognostic Significance of Somatic Mutations in the Tyrosine Kinase (Tk) Domain of Egfr in Nsclc Patients Treated with Single Agent Gefitinib: A Systematic Review and Meta-AnalysisMurray, S.; Evangelou, E.; Linardou, H.; Kosmidis, P.; Bafaloukos, D.; Ioannidis, J.24-Nov-2015-
Predictive Significance of Egfr Somatic Mutations and Gene Copy Number in Nsclc Patients Treated with Single Agent Tyrosine Kinase Inhibitors: A Systematic Review and Meta-AnalysisMurray, S.; Evangelou, E.; Linardou, H.; Dahabreh, I. J.; Kosmidis, P.; Bafaloukos, D.; Ioannidis, J. P. A.24-Nov-2015-
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group StudyFostira, F.; Tsitlaidou, M.; Papadimitriou, C.; Pertesi, M.; Timotheadou, E.; Stavropoulou, A. V.; Glentis, S.; Bournakis, E.; Bobos, M.; Pectasides, D.; Papakostas, P.; Pentheroudakis, G.; Gogas, H.; Skarlos, P.; Samantas, E.; Bafaloukos, D.; Kosmidis, P. A.; Koutras, A.; Yannoukakos, D.; Konstantopoulou, I.; Fountzilas, G.24-Nov-2015-
Prognostic variables in greek patients with stage II breast cancer: a Hellenic Cooperative Oncology Group studyFountzilas, G.; Vasilaros, S.; Koukouras, D.; Malamos, N.; Pectasides, D.; Adamou, A.; Nenopoulou, E.; Kiriakou, K.; Zouvani, I.; Katsohis, K.; Kappas, A.; Skopa, C.; Semoglou, C.; Fahantidis, E.; Konstantaras, C.; Vasilaki, E.; Economopoulos, T.; Bacoyiannis, H.; Bafaloukos, D.; Razi, E.; Polichronis, A.; Androulakis, G.; Papaioannou, T.; Pavlidis, N.; Kosmidis, P.; et al.,24-Nov-2015-
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group StudyKalofonos, H. P.; Bamias, A.; Koutras, A.; Papakostas, P.; Basdanis, G.; Samantas, E.; Karina, M.; Misailidou, D.; Pisanidis, N.; Pentheroudakis, G.; Economopoulos, T.; Papadimitriou, C.; Skarlos, D. V.; Pectasides, D.; Stavropoulos, M.; Bafaloukos, D.; Kardamakis, D.; Karanikiotis, C.; Vourli, G.; Fountzilas, G.24-Nov-2015-
A randomized open-label parallel-group study comparing ondansetron with ondansetron plus dexamethasone in patients with metastatic breast cancer receiving high-dose epirubicin. A Hellenic Cooperative Oncology Group studyJaninis, J.; Giannakakis, T.; Athanasiadis, A.; Fountzilas, G.; Bafaloukos, D.; Kosmidis, P.; Nikolaides, K.; Pavlidis, N.; Skarlos, D.24-Nov-2015-
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group studyBafaloukos, D.; Linardou, H.; Aravantinos, G.; Papadimitriou, C.; Bamias, A.; Fountzilas, G.; Kalofonos, H. P.; Kosmidis, P.; Timotheadou, E.; Makatsoris, T.; Samantas, E.; Briasoulis, E.; Christodoulou, C.; Papakostas, P.; Pectasides, D.; Dimopoulos, A. M.24-Nov-2015-